Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Cancer Immunotherapy: Update Bulletin [December 2015]

Product Code:
596200536
Publication Date:
December 2015
Format:
PDF
Price:
£1,140

Gain new payer insights on the latest events with the potential to shape the cancer immunotherapy market. Topics covered include recent drug approvals, such as the combination of Bristol-Myers Squibb’s Opdivo and Yervoy for the treatment of BRAF V600 wild-type unresectable or metastatic melanoma, as well as the expanded approval of Merck & Co.'s Keytruda for non-small cell lung cancer (NSCLC), and Opdivo monotherapy for previously untreated BRAF wild-type unresectable or metastatic melanoma. Payer insights were also sought on the need for PD-L1 testing for reimbursement decisions and on cost management strategies as checkpoint inhibitors acquire broader indications. 

Key Questions Answered in this Update Bulletin:

  • Given the high price tag, how widely do US payers expect to cover the recently approved combination of Opdivo and Yervoy for BRAF V600 wild-type unresectable or metastatic melanoma?
  • How will reimbursement decisions change, if the combination of Opdivo and Yervoy gains extended approval for NSCLC?
  • What factors will be considered in reimbursement decisions for the combination of Opdivo plus Yervoy?
  • Opdivo monotherapy recently gained extended approval for BRAF V600 wild-type unresectable or metastatic melanoma. What methods will payers employ to choose between this and the high cost combination of Yervoy plus Opdivo?
  • Will PD-L1 testing be required before allowing access to the combination of Yervoy plus Opdivo or Opdivo monotherapy?
  • What are payers’ reactions to the expanded approval of Keytruda to include NSCLC and how widely will it be covered?
  • How will payers choose between Keytruda and Opdivo for the treatment of NSCLC, given that both drugs are now available for the same indication and PD-L1 testing is required by label for Keytruda but not for Opdivo?
  • How important is continued ongoing verification of data for providing access to cancer immunotherapies?
  • How will companion diagnostic tests impact pricing and reimbursement decisions for cancer immunotherapy drugs?
  • What are payers’ views on contracting cancer immunotherapies through preferred therapy rebates?
  • What long-term cost management strategies do payers envisage for cancer immunotherapies?
  • What data are likely to reduce payers’ aversion to risk-sharing contracts for cancer immunotherapies?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved